Jack Y. Zhang

This profile gathers the share dealings of Jack Y. Zhang in Amphastar Pharmaceuticals, Inc., where the filings describe the role as chief executive. Over a trading history stretching from 26 March 2015 to 15 March 2026, the count stands at 224 filings.

In open-market terms, that means 2 purchases worth €544k on one side and 62 sales worth €38.8M on the other. Sales outweigh purchases by €38.3M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 113 share grants and 43 option exercises.

On 17 March 2026 came the latest disclosure, a share grant for €46k in Amphastar Pharmaceuticals, Inc. The most recent open-market purchase was published on 17 May 2018, 3,084 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.